Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841784 · ClinicalTrials.gov registry record · NA
HARP Mindfulness Study
A NA study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT05841784: Recruiting NA study, sponsored by NYU Langone Health.
NCT05841784 is a NA study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841784, a NA study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
This study was designed using the Multiphase Optimization Strategy (MOST) framework to determine whether two supplemental components increase the efficacy of a mindfulness-based cognitive therapy program delivered via telephone (MBCT-T) for psychological distress. Specifically, this study will test mindfulness booster sessions to follow a standard 8-week MBCT-T intervention, as well as website support in patients with heart disease and/or heart disease risk factors.
Primary Outcome
Composite score of 3 questionnaires. The total composite score is the sum of scores from the questionnaires and ranges from 0 to 88; lower scores indicate greater overall health. PSS-10 measures perceived stress over the past month. Items rated on a 5-point scale ranging from 0 (never) to 4 (very often). Total scores range from 0-40; higher scores indicate greater levels of perceived stress. PHQ-9 assesses depressive symptoms in the past two weeks. Items rated on a 4-point scale ranging from 0
Interventions
- BEHAVIORAL MBCT-T
- BEHAVIORAL Booster Mindfulness Sessions
- BEHAVIORAL Website Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05841784 shows while recruiting
NCT05841784 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which MBCT-T is the first listed.
NCT05841784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05841784 about?
NCT05841784 is a clinical study titled "HARP Mindfulness Study". This study was designed using the Multiphase Optimization Strategy (MOST) framework to determine whether two supplemental components increase the efficacy of a mindfulness-based cognitive therapy program delivered via telephone (MBCT-T) for psychological distress. Specifically, this study will test ...
What is the current status of trial NCT05841784?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-05-15. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT05841784?
The interventions under investigation include: MBCT-T (BEHAVIORAL), Booster Mindfulness Sessions (BEHAVIORAL), Website Support (BEHAVIORAL).
Who is sponsoring clinical trial NCT05841784?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05841784's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI